Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148446 | 0.97 | PDCD1LG2 (0.43) | PDCD1LG2CD274MMEBACE1CTSD | |
| SCHEMBL29531582 | 0.92 | PDCD1LG2 (0.47) | PDCD1LG2CD274MMESMN1; SMN2ALDH1A1 | |
| SCHEMBL29777795 | 0.92 | PDCD1LG2 (0.47) | PDCD1LG2CD274MMESMN1; SMN2ALDH1A1 | |
| SCHEMBL16870893 | 0.92 | PDCD1LG2 (0.47) | PDCD1LG2CD274MMESMN1; SMN2ALDH1A1 | |
| SCHEMBL30728894 | 0.89 | MME (0.46) | MMEBACE1CTSDOPRM1OPRD1 | |
| SCHEMBL29407393 | 0.89 | BACE1 (0.43) | PDCD1LG2CD274MMEALDH1A1BACE1 | |
| SCHEMBL30053992 | 0.89 | PDCD1LG2 (0.48) | PDCD1LG2CD274MMEBACE1CTSD | |
| SCHEMBL29658152 | 0.89 | CD274 (0.56) | PDCD1LG2CD274MMEOPRM1OPRD1 | |
| SCHEMBL30123248 | 0.89 | CD274 (0.56) | PDCD1LG2CD274MMEOPRM1OPRD1 | |
| SCHEMBL29930416 | 0.89 | MME (0.40) | PDCD1LG2CD274MMESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114848812-A | Neutralizing antibodies against human immunodeficiency virus | 吉利德科学公司 | 2022-08-05 | — | — | CN | claimed |
| EP-3992206-A1 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | Gilead Sciences, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| CN-122005785-A | Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies | 吉利德科学公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3972645-B9 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | GILEAD SCIENCES INC (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119591699-A | Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies | 吉利德科学公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4513188-A2 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | Gilead Sciences, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250059261-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. | 2025-02-20 | — | — | US | disclosed |
| US-20250041401-A1 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12195524-B2 | Multi-specific antigen binding molecules targeting HIV and methods of use | GILEAD SCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-114848812-B | Human immunodeficiency virus neutralizing antibodies | 吉利德科学公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3972645-B1 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | GILEAD SCIENCES INC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12102677-B2 | Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies | GILEAD SCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| US-11851694-B1 | High fidelity in vitro transcription | MODERNATX, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11655285-B2 | Human immunodeficiency virus neutralizing antibodies | GILEAD SCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230056252-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-114848812-A | Neutralizing antibodies against human immunodeficiency virus | 吉利德科学公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3992206-A1 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | Gilead Sciences, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |